Our next step was to investigate cell death in CML cells treated with the TRPV1 agonist OLDA, given that the UPR pathway may play a dual role in either providing survival benefits or triggering cell death (Mlynarczyk and Fåhraeus, 2014). This evidence concerns the gene TRPV1 and chronic myelogenous leukemia, BCR-ABL1 positive.